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Objectives The aim of this study was to evaluate the safety as well as the clinical and technical effectiveness of robotic-
assisted percutaneous coronary intervention.
Background Robotic systems have been suggested to enhance the performance of cardiovascular procedures, as well as to
provide protection from the occupational hazards that are associated with interventional practice.
Methods Patients with coronary artery disease and clinical indications for percutaneous intervention were enrolled. The coro-
nary intervention was performed with the CorPath 200 robotic system, which consists of a remote interventional
cockpit and a bedside disposable cassette that enables the operator to advance, retract, and rotate guidewires and
catheters. The primary endpoints were clinical procedural success, defined as 30% residual stenosis at the comple-
tion of the robotic-assisted procedure without major adverse cardiovascular events within 30 days, and device techni-
cal success, defined as the successful manipulation of the intracoronary devices using the robotic system only.
Results A total of 164 patients were enrolled at 9 sites. Percutaneous coronary intervention was completed successfully
without conversion to manual operation, and device technical success was achieved in 162 of 164 patients
(98.8%). There were no device-related complications. Clinical procedural success was achieved in 160 of 164
patients (97.6%), whereas 4 (2.4%) had periprocedural non–Q-wave myocardial infarctions. No deaths, strokes,
Q-wave myocardial infarctions, or revascularization occurred in the 30 days after the procedures. Radiation expo-
sure for the primary operator was 95.2% lower than the levels found at the traditional table position.
Conclusions This pivotal multicenter study with a robotic-enhanced coronary intervention system demonstrated the safety
and feasibility of the system. The robotic remote-control procedure met the expected technical and clinical per-
formance, with significantly lower radiation exposure to the operator. (Evaluation of the Safety and Effectiveness
of the CorPath 200 System in Percutaneous Coronary Interventions [PCI] [PRECISE]; NCT01275092) (J Am
Coll Cardiol 2013;61:1596–600) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.12.045A remote-controlled robotic system was designed to
address some of the procedural challenges and occupa-
tional hazards associated with traditional percutaneous
coronary intervention (PCI) in addition to enhancing the
degree of precision and control for the interventional
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This was a prospective, single-arm, multicenter, open-label,
nonrandomized study. The study protocol was approved by
the institutional review boards or local ethics committees of
the participating facilities, and all patients provided written
informed consent.
The objectives of this study were to evaluate the safety, clinical,
and technical performance of the robotic system in the delivery
and manipulation of coronary guidewires, balloons, and stents for
PCI.
Patients. Patients with angiographic documentation of
obstructive coronary artery disease and evidence of myocar-
dial ischemia were enrolled in the study. Major inclusion
criteria included a de novo stenosis of at least 50% by visual
estimate, with maximal length of 24 mm and reference
diameter of 2.5 to 4.0 mm, that could be completely covered
by a single stent. Major clinical exclusion criteria included
planned PCI or coronary artery bypass graft surgery, re-
quired treatment of more than 1 coronary artery, previous
stent implantation within 5.0 mm of the target lesion,
planned treatment with directional or rotational atherec-
tomy, intraluminal thrombus, severe tortuosity or calcifica-
tion of the lesion or proximal to it, total occlusion, ostial
location, involvement of a bifurcation, or unprotected left
main coronary artery.
Post-procedural creatine kinase and its myocardial band
isoenzyme were routinely measured at 8 and 16 to 24 h, and
all patients were followed for clinical events throughout
their hospital stays and for 30 days afterward.
Robotic system. All patients underwent PCI with the
robotic CorPath 200 System (Corindus Vascular Robotics,
Natick, Massachusetts). The system was designed for cor-
onary PCI and consists of 2 major components: the inter-
Figure 1 The CorPath 200 Robotic System
in the Catheterization Laboratory
On the right, the operator sits in the shielded interventional cockpit, performing
the interventional procedure by remotely controlling the robotic cassette (red
arrow) that is connected to the guiding catheter. The intracoronary devices
(guidewire, balloon, and stent catheters) are loaded into the sterile cassette.ventional cockpit and a bedside unit (Fig. 1). The interven-tional cockpit is a radiation-shielded,
mobile workstation that was posi-
tioned in the corner of the catheter-
ization laboratory. The interven-
tional cardiologist sits at the cockpit
and remotely performs the PCI us-
ing the console joysticks or touch-screen buttons. Commands
from the control console are delivered as electrical signals
along a communication cable that runs from the control
console to the robotic drive, on which a sterile cassette is
placed. The cassette, which is loaded with the interventional
devices and connected to the guiding catheters, imposes
axial and rotational forces on the intracoronary devices. The
robotic-assisted system is compatible with all commercially
available 0.014-inch guidewires, rapid-exchange coronary
angioplasty balloons, and stent delivery systems. Fluoro-
scopic, electrocardiographic, and hemodynamic images are
“slaved” to the duplicate monitors inside the cockpit, en-
abling visualization from a closer distance. All operators had
training on the system that included either animal labora-
tory experience or using a high-fidelity simulator before
enrolling patients in the study.
After completion of diagnostic angiography, the guiding
catheter was positioned at the ostium of the coronary artery
and connected to the disposable cassette on the robotic
drive. The guidewire was loaded into the cassette before
starting the robotic-enhanced PCI. Anticoagulation was
administrated according to local site protocols. Pre-dilation
was mandated by protocol, and post-dilation was done per
operator discretion. All intracoronary devices were to be
manipulated exclusively by the robotic system, with bailout
to manual conversion when needed.
Study endpoints. The 2 primary endpoints were clinical
procedural success and device technical success.
Clinical procedural success was defined as 30% residual
stenosis at the completion of the procedure of robotically-
treated lesions as determined by a quantitative coronary
angiographic core laboratory, in the absence of major
adverse cardiovascular events, either within 48 h of the
procedure or before hospital discharge, whichever occurred
first. Major adverse cardiovascular events were defined as
cardiac death, Q-wave or non–Q-wave myocardial infarc-
tion, or clinically driven target vessel revascularization.
Non–Q-wave myocardial infarction was defined as elevated
creatine kinase myocardial band isoenzyme 3 times the
upper limit of normal in the absence of new pathological Q
waves. All events were adjudicated by an independent
clinical events committee.
Device technical success was defined as the successful
intracoronary advancement and retraction of the PCI de-
vices (guidewire, angioplasty balloon, and stent) by the
robotic system, without conversion to manual operation.
The radiation exposure to the operator at the interven-
tional cockpit and at the procedure table were monitored
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the endpoint of clinical procedural success was calculated on
the basis of the Fisher exact test using assumptions of an
expected rate of clinical procedural success of 91.6% and
type I error () of 0.05 (1-sided). A sample size of 163
would provide 90% power to reject the null hypothesis,
signifying that the CorPath 200 System met the perfor-
mance goal for clinical procedural success. For device
technical success, a lower limit of the 1-sided 95% confi-
dence interval of 90.0% and statistical power of 90%, the
true rate of device technical success would need to be higher
than 94.5% to reject the null hypothesis, assuming 163
patients. Both primary endpoints had to be met for the
study to be declared successful.
Data were analyzed on an intention-to-treat basis. Stan-
dard summary statistics were calculated for all patient and
study outcome variables. Continuous variables were summa-
rized using estimated means, standard deviations, minimums,
maximums, medians, and interquartile ranges. Categorical data
were summarized using frequencies, percentages, and 95%
confidence intervals.
The powered secondary effectiveness endpoint of a re-
duction in operator radiation exposure (the median ratio of
operator dose to table dose) was evaluated using an ordinal
test for paired samples (the Wilcoxon signed rank test). The
alternative hypothesis formulated for the study to be
successful was to achieve a minimum of 50% reduction in
the operator’s radiation exposure compared with the
radiation exposure measured at the procedure table dur-
ing the procedure.
Results
A total of 164 patients from 9 sites met the inclusion and
exclusion criteria and underwent PCI using the robotic system.
Baseline clinical characteristics and quantitative coronary an-
giographic findings are detailed in Tables 1 and 2.
Patients Demographics andB s line Characteristics (n  164)Table 1 P tient Demographics andBaseline Characteristics (n  164)
Age (yrs) 64.1 10.0
Men 74.4%
Hypertension 141 (86%)
Diabetes mellitus 58 (35.4%)
Hyperlipidemia 145 (88.4%)
Prior myocardial infraction 83 (50.6%)
Prior PCI 129 (78.7%)
Prior CABG 10 (6.1%)
Prior stroke or TIA 14 (8.5%)
Peripheral vascular disease 29 (17.7%)
Left ventricular ejection fraction (%) 54.9 8.9
Indication for PCI
Stable angina 47 (28.7%)
Unstable angina 94 (57.3%)
Values are mean  SD or n (%).
CABG  coronary artery bypass grafting; PCI  percutaneous coronary intervention;
TIA  transient ischemic attack.All PCI procedures were performed via femoral arterial
access, with 6-F guiding catheters in 119 (72.6%) and 7-F
guiding catheters in 45 (27.4%). All devices (guide cathe-
ters, guidewires, balloons, and stents) were commercially
approved and selected by the operator, similarly to manual
PCI. A mean of 1.1  0.34 stents were deployed per
patient. In 12 patients, more than 1 stent was used to treat
stent-edge dissection or plaque shift. post-dilation was
performed in 33 patients (20.1%). In 162 procedures
(98.8%), the entire procedure was performed with the
robotic system, with successful advancing and retrieving of
all intracoronary devices. In all patients, advancements of
the guidewire proceeded uneventfully, without any dissec-
tion or perforation and no injury related to the guiding
catheter. In all patients (except for 1 in whom it was
unintentionally omitted), the pre-dilation balloon was suc-
cessfully delivered to the lesion, inflated, and successfully
retrieved by the robotic system back into the guiding
catheter. In 2 procedures (1.2%), the operators converted to
manual operation because of severe resistance to delivery of
the stent. In both cases, the procedure was also difficult to
perform manually and was completed successfully only after
upgrading to a more supportive guiding catheter and the use
of advanced interventional techniques, including buddy
wires and the use of a GuideLiner (Vascular Solutions, Inc.,
Minneapolis, Minnesota). The conversion to manual oper-
ation was immediate and not associated with myocardial
ischemia, hemodynamic compromise, or any other compli-
cations. In both cases, there were no periprocedural com-
Quantitative Angiographic AnalysisTable 2 Quantitative Angiographic Analysis
Variable Pre-Procedure Post-Procedure
LAD 55 (33.5%)
Main LAD 53 (32.3%)
Diagonal 2 (1.2%)
LCX 47 (28.7%)
Main LCX 35 (21.3%)
Ramus intermedius 8 (4.9%)
Obtuse marginal 4 (2.4%)
RCA 62 (37.8%)
Main RCA 60 (36.6%)






Lesion length (mm) 12.2 4.8
Reference vessel diameter (mm) 2.66 0.45 2.73 0.46
MLD (mm) 0.95 0.33 2.59 0.43
Diameter stenosis (%) 64.10 10.9 4.90 7.85
Values are n (%) or mean  SD.
ACC  American College of Cardiology; AHA  American Heart Association; LAD  left anterior
descending coronary artery; LCX  left circumflex coronary artery; MLD  minimal luminal
iameter; RCA  right coronary artery.plications or myocardial enzyme elevations.
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Thrombolysis In Myocardial Infarction flow grade 3. There
were no clinical adverse events related to the use of the
robotic system. The mean robotic system procedure time
was 24.4  14.1 min with a mean fluoroscopy time of 11.1 
6.2 min. The mean patient cumulative dose was 1.5  0.8
Gy. The mean contrast media volume used was 144.2 
70.4 ml.
Clinical outcomes are detailed in Table 3. The primary
endpoint of clinical procedural success was achieved in
97.6% of patients (160 of 164), with the 1-sided exact 95%
confidence interval yielding a lower bound of calculated
performance goal at 94.5%, significantly higher than the
protocol-specified performance goal of 84% (p  0.001). In
4 patients (2.4%), there were modest post-procedural ele-
vations in myocardial biomarkers corresponding to the
definition of non–Q-wave myocardial infarction. Device
technical success was achieved in 162 of 164 patients
(98.8%), with the 1-sided exact 95% confidence interval
yielding a lower bound of calculated performance goal at
96.2%, significantly higher than the protocol-specified
performance goal of 90% (p  0.001). Thus, both
primary endpoints were successfully met at a high level of
significance.
The powered secondary effectiveness endpoint of a min-
imum 50% reduction in operator radiation exposure was
successfully met. The median radiation exposure to the
operators at the interventional cockpit was 95.2% lower than
In-Hospital and 30-Day Follow-Up Outcomes (n  164)Table 3 In-Hospital and 30-Day Follow-Up Outcomes (n  164)
In-hospital
Death 0 (0.0)





Out-of-hospital to 30 days
Death 0 (0.0)





All events to 30-day follow-up
Death 0 (0.0)





Stent thrombosis, 0–30 days 0 (0.0)
Values are n (%). All events were adjudicated by the clinical events committee.
MACEmajor adverse cardiovascular event(s); MImyocardial infarction; TLR target lesion
evascularization.at the procedure table (0.98 vs. 20.6 Gy, p  0.0001).Discussion
The prospective multicenter PRECISE (Percutaneous
Robotically-Enhanced Coronary Intervention) study dem-
onstrated the safety and feasibility of remote-controlled PCI
using the CorPath 200 robotic system. In 164 patients
treated by 23 operators, there were no system-related
complications and no major clinical events. Only 4 patients
(2.4%) had periprocedural myocardial biomarker elevations,
without clinical consequences. The primary endpoint of
clinical procedural success was achieved in 97.6%, and
device technical success was achieved in 98.8%. In only 2
patients was conversion to traditional manual operation
required.
This is the first large multicenter study of a remote-
controlled robotic system. Animal studies have shown that
the robotic system tested in this study is safe and effective in
the manipulation of interventional devices into normal
porcine coronary arteries. Histological evaluation of the
coronary arteries showed similar injury scores and vascular
healing patterns when the robotic system was compared
with manually treated vessels (1,2). An early experimental
robotic system proved to be safe and feasible (3). The first
human experience in 8 PCI cases with the currently studied
CorPath 200 system demonstrated 97.8% technical success
rate by completing 47 of 48 procedural segments, without
major adverse cardiovascular events (4).
Remote-controlled robotic systems are expected to reduce
occupational hazards to interventional cardiologists. As the
current practice of interventional cardiology evolves into
more complex procedures, interventional cardiologists and
professional societies have called for improved catheteriza-
tion laboratory safety by reducing radiation exposure to
both patients and operators and making the catheteriza-
tion laboratory more ergonomically friendly through
technological innovations (5–7). Interventional cardiolo-
gists develop posterior lens opacities and cataracts at
younger ages and at higher rates than other professionals
(6,8,9). A recent observational report raised concern for a
possible association of career-long exposure to radiation
in interventional cardiologists with the development of
left-sided brain tumors (10).
In the present study, we measured the radiation exposure
to the operator seated in the shielded interventional cockpit
and compared it with radiation exposure at the procedure
table. We found a significant decrease in operator radiation
exposure, with a median reduction of 95.2%. The mean
fluoroscopy time and patient radiation exposure compare
favorably with previously published results (11).
Another occupational hazard for the interventional car-
diologist is orthopedic injury. Long hours donning a heavy
lead apron while standing may adversely affect interven-
tional cardiologists, resulting in reduced performance and
loss of productivity (12). Although no measurement of
“operator comfort” was used in this study, the benefits of the
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Robotic-Enhanced PCI April 16, 2013:1596–600cockpit without the need for a heavy lead apron minimizes
back discomfort, allowing the operator to focus on the
procedure without being distracted by the physical strain.
Study limitations. Although it was a registry without a
ontrol group, all patient characteristics, angiographic fea-
ures, and procedural parameters were comparable with
ublished data, including patient exposure to radiation and
he volume of contrast media used (11). Although the
esions that were treated in this study were relatively simple,
hey do not differ from the types of lesions usually studied in
rospective PCI studies.
onclusions
ncorporating a remote-controlled, robotic-assisted PCI
ystem into the catheterization laboratory addresses some of
he occupational hazards associated with PCI, without
ffecting procedural performance and patient safety.
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